| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Microbiology and Immunology and
Neurology, The Medical School, Newcastle, United Kingdom
As a potential means for facilitating studies of NK cell-related
molecules, we examined the expression of these molecules on a range of
mouse tumor cell lines. Of the lines we initially examined, only EL4
and RMA expressed such molecules, both lines expressing several members
of the Ly49 and NKRP1 families. Unexpectedly, several of the NK-related
molecules, together with certain other molecules including CD2, CD3,
CD4, CD32, and CD44, were often expressed in a mosaic manner, even on
freshly derived clones, indicating frequent switching in expression. In
each case examined, switching was controlled at the mRNA level, with
expression of CD3
determining expression of the entire CD3-TCR
complex. Each of the variable molecules was expressed independently,
with the exception that CD3 was restricted to cells that also expressed
CD2. Treatment with drugs that affect DNA methylation and histone
acetylation could augment the expression of at least some of the
variable molecules. The striking phenotypic similarity between EL4 and
RMA led us to examine the state of their TCRß genes. Both lines had
identical rearrangements on both chromosomes, indicating that RMA is in
fact a subline of EL4. Overall, these findings suggest that EL4 is an
NK-T cell tumor that may have retained a genetic mechanism that permits
the variable expression of a restricted group of molecules involved in
recognition and signaling.
This article has been cited by other articles:
|
|
 |
|
  V. Pascal, N. R. Nathan, E. Claudio, U. Siebenlist, and S. K. Anderson NF-{kappa}B p50/p65 Affects the Frequency of Ly49 Gene Expression by NK Cells J. Immunol., August 1, 2007; 179(3): 1751 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vanherberghen, K. Andersson, L. M. Carlin, E. N. M. Nolte-`t Hoen, G. S. Williams, P. Hoglund, and D. M. Davis Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells PNAS, November 30, 2004; 101(48): 16873 - 16878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Saleh, A. P. Makrigiannis, D. L. Hodge, and S. K. Anderson Identification of a Novel Ly49 Promoter That Is Active in Bone Marrow and Fetal Thymus J. Immunol., May 15, 2002; 168(10): 5163 - 5169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tantin and P. A. Sharp Mouse Lymphoid Cell Line Selected To Have High Immunoglobulin Promoter Activity Mol. Cell. Biol., March 1, 2002; 22(5): 1460 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gays, K. P. Fraser, J. A. Toomey, A. G. Diamond, M. M. Millrain, P. J. Dyson, and C. G. Brooks Functional Analysis of the Molecular Factors Controlling Qa1-Mediated Protection of Target Cells from NK Lysis J. Immunol., February 1, 2001; 166(3): 1601 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. van Hall, J. van Bergen, P. A. van Veelen, M. Kraakman, L. C. Heukamp, F. Koning, C. J. M. Melief, F. Ossendorp, and R. Offringa Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin J. Immunol., July 15, 2000; 165(2): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
